SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells.

Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M. · 2012

Read SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. by Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3494655.txt.

Introduction

Resting CD4 T cells resist HIV-1, and Benjamin Descours and nine colleagues pin that resistance on one protein in 2012. The block sits at reverse transcription, the step where the virus copies its RNA into DNA.

SAMHD1 is present in both CD4 and CD8 T cells at levels matching myeloid cells. Removing it with virus-like particles carrying Vpx lets HIV-1 infect resting cells and build viral DNA, without switching on viral gene expression. CD4 cells from Aicardi-Goutieres syndrome patients, who carry mutated SAMHD1, are already more infectable, and Vpx adds nothing. SAMHD1, the study concludes, is the restriction factor guarding quiet T cells.

Catalog record

CREATORDescours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3494655

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells By Benjamin Descours, Alexandra Cribier, Christine Chable-Bessia, Diana Ayinde, Gillian Rice, Yanick Crow, Ahmad Yatim, Olivier Schwartz, Nadine Laguette, Monsef Benkirane Published in: Retrovirology DOI: 10.1186/1742-4690-9-87 ABSTRACT Abstract Background Quiescent CD4+ T lymphocytes are highly refractory to HIV-1 infection due to a block at reverse transcription. Results Examination of SAMHD1 expression in peripheral blood lymphocytes shows that SAMHD1 is expressed in both CD4+ and CD8+ T cells at levels comparable to those found in myeloid cells. Treatment of CD4+ T cells with Virus-Like Particles (VLP) containing Vpx results in the loss of SAMHD1 expression that correlates with an increased permissiveness to HIV-1 infection and accumulation of reverse transcribed viral DNA without promoting transcription from the viral LTR. Importantly, CD4+ T-cells from patients with Aicardi-Goutières Syndrome harboring mutation in the SAMHD1 gene display an increased susceptibility to HIV-1 infection that is not further enhanced by VLP-Vpx-treatment. Conclusion Here, we identified SAMHD1 as the restriction factor preventing efficient viral DNA synthesis in non-cycling resting CD4+ T-cells. These results highlight the crucial role of SAMHD1 in mediating restriction of HIV-1 infection in quiescent CD4+ T-cells and could impact our understanding of HIV-1 mediated CD4+ T-cell depletion and establishment of the viral reservoir, two of the HIV/AIDS hallmarks. Keywords: SAMHD1, Quiescent CD4+ T-cell, HIV-1, Reverse transcription, Restriction BACKGROUND The human immunodeficiency virus type-1 (HIV-1) primarily infects CD4+ T-cells. While activated lymphocytes support viral replication, non-cycling quiescent CD4+ T-cells allow entry of HIV-1 but fail to allow efficient and complete reverse transcription [1-6]. However, addition of deoxynucleosides to unstimulated lymphocytes cultures partially overcomes this failure [7-9], suggesting that an insufficient supply of deoxynucleotide triphosphates (dNTPs) in quiescent T-cells may, at least in part, contribute to inefficient viral DNA synthesis [8,10]. Interestingly, the Aicardi-Goutières syndrome gene product SAMHD1 was recently described as the restriction factor that blocks HIV-1 infection of non-cycling myeloid cells [11-13]. SAMHD1 is a dGTP-dependent deoxynucleotide triphosphohydrolase [14-16] that reduces the cellular pool of dNTPs in differentiated, non-cycling myeloid cells to levels below those required to support HIV-1 DNA synthesis [15,17]. However, SAMHD1’s spectrum of activity beyond cells of the myeloid lineage remains unclear. RESULTS AND DISCUSSION We first determined whether SAMHD1 was expressed in peripheral blood lymphocytes from healthy donors. Western blot analysis revealed that both CD4+ and CD8+ T-cells express SAMHD1 (Figure 1a). The expression levels of SAMHD1 in unstimulated CD4+ T-cells were similar to those found in myeloid cells, including CD14+ monocytes, monocytes-derived macrophages (MDM) and monocyte-derived dendritic cells (MDDC) (Figure 1a). Moreover, flow cytometry analysis revealed that all circulating CD4+ T-cells subsets, including naïve (Tn; CD45RA+, CCR7+), central memory (Tcm; CD45RA-, CCR7+) and effector memory cells (Tem; CD45RA-, CCR7-), expressed high levels of SAMHD1 (Figure 1b), raising the possibility that SAMHD1 could affect the susceptibility of resting CD4+ lymphocytes to HIV-1 infection. [Figure: CD4 T lymphocytes express SAMHD1.a. Western blot analysis of SAMHD1 expression in primary hematopoietic cells. b. Flow cytometry analysis of SAMHD1 expression levels in CD14+ monocytes, T-cells (CD4+ and CD8+ T lymphocytes) and in CD4+ T-cell subsets including Naïve (Tn; CD45RA+, CCR7+), Central Memory (Tcm; CD45RA-, CCR7+), and Effector Memory (Tem; CD45RA-, CCR7-). c. Kinetics of SAMHD1 loss in quiescent (CD69-, HLA-DR-) CD4+ T-cells after VLP-Vpx treatment (representative experiment, n = 2). d. Vpx transduction of activated CD4+ T-cells induces loss of SAMHD1. TCR-stimulated CD4+ T-cells were transduced with Vpx-HA expressing retroviral construct. Forty-eight hours later, SAMHD1 and Vpx were immunostained using specific antibodies. Nuclei were stained in mounting media with DAPI. Pie charts represent the proportions of SAMHD1+ cells among 100 Vpx positive and negative counted cells.] To test this hypothesis, we exposed unstimulated peripheral blood mononuclear cells (PBMCs) to viral-like particles containing the SIV accessory protein Vpxmac251 (VLP-Vpx), which counteracts SAMHD1-mediated restriction by triggering its proteasomal degradation [12,13]. PBMCs treated with VLP-Vpx or empty VLPs (VLP-Mock) were analyzed for SAMHD1 expression by flow cytometry. An average of 16% of VLP-Vpx treated resting CD4+ T-cells were SAMHD1 negative at 96 hours post-exposure (Figure 1c), whereas most monocytes (90.2%) lost the expression of SAMHD1 after 48 hrs of VLP-Vpx treatment (Additional file 1: Figure S1). The difference in Vpx-mediated loss of SAMHD1 in quiescent CD4+ T-cells and monocytes might result from discrepancies in nuclear/cytoplasmic exchange [18]. Indeed, we have recently shown that Vpx-mediated degradation of SAMHD1 requires its nuclear export [19,20]. In support of this hypothesis, loss of SAMHD1 expression was observed in more than 80% of T-cell receptor (TCR)-stimulated CD4+ lymphocytes expressing Vpx (Figure 1d). We next evaluated the effect of SAMHD1 loss on HIV-1-resistance phenotype of resting CD4+ T-cells. Restriction of HIV-1 replication in quiescent T-cells has been attributed to blocks at both the reverse transcription step and viral gene expression (e.g.: lack of transcription factors such as NF-kB and CyclinT required for viral transcription) [21,22]. Thus, to bypass the transcriptional block, we performed single-round infection experiments using an HIV-1 based lentiviral vector carrying an EGFP cassette under the transcriptional control of the CMV promoter (HIV-CMV-EGFP). Unstimulated PBMCs isolated from healthy donors were exposed for 12 hrs to VLP-Vpx or VLP-Mock and subsequently infected with HIV-CMV-EGFP. As expected, no EGFP was detected when cells were treated with VLP-Mock (Figure 2a), while, VLP-Vpx treatment resulted in EGFP expression in quiescent (HLA-DR-, CD69-) CD4+ T-cells (Figure 2a). An average of 14% of VLP-Vpx treated resting CD4+ T lymphocytes expressed EGFP, while less than 1% of cells exposed to VLP-Mock were EGFP+ (Figure 2a and Additional file 1: Figure S2a). As a control, VLP-Vpx treatment enhanced the permissiveness of CD14+ monocytes to HIV-CMV-EGFP (Additional file 1: Figure S3b). These results indicate that Vpx could alleviate the post-entry block to HIV-1 infection of unstimulated T-cells. Importantly, VLP-Vpx treatment was not associated with CD4+ T-cell activation (Additional file 1: Figure S2c) or proliferation (Figure 2b). Vpx increased the susceptibility of non-cycling quiescent T-cells (eFluorHigh) (Figure 2b) while it had no effect on the permissiveness of activated dividing T-cells (eFluorLow) despite high level expression of SAMHD1 (Additional file 1: Figure S2d). In addition, Vpx increased HIV-1 infection of all resting CD4+ T subsets, including highly refractory naïve cells (Tn) (Figure 2c). [Figure: Vpx treatment of quiescent CD4+T-cells results in increased susceptibility to HIV-1 infection.a. Impact of Vpx treatment on quiescent CD4+ T-cells susceptibility to HIV-CMV-EGFP infection. Upper right panel: expression vectors used to produce HIV-CMV-EGFP virions. Left panel: PBMCs were treated 12 h with VLP-Mock or VLP-Vpx then infected with HIV-CMV-EGFP or uninfected (control). Proportions of EGFP positive quiescent CD4+ T-cells (CD69- HLA-DR-) were assessed 4 days post infection. Lower right panel: Results are expressed as percentage of EGFP positive cells. Graphic shows mean and standard deviation for 6 healthy donors. b. PBMCs were cultured as in a. after staining with the eFluor670 proliferation dye. Cell division and EGFP expression were assessed in CD4+ T-cells (a representative experiment is shown). c. Impact of Vpx on quiescent CD4+ T-cell subsets susceptibility to HIV-CMV-EGFP infection. Left panel: gating strategy to define CD4+ T-cell subsets: Naïve (Tn; CD45RA+, CCR7+), Central Memory (Tcm; CD45RA-, CCR7+) and Effector Memory (Tem; CD45RA-, CCR7-). Middle panel: Permissiveness of Tn, Tcm and Tem to HIV-CMV-EGFP performed as described in a (a representative experiment; n = 3). d. Kinetics of

Read the complete text